Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Saved in:
| Title: | Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. |
|---|---|
| Authors: | Hopcroft, Lorna, Wigmore, Eleanor M., Williamson, Stuart C., Ros, Susana, Eberlein, Cath, Moss, Jennifer I., Urosevic, Jelena, Carnevalli, Larissa S., Talbot, Sara, Bradshaw, Lauren, Blaker, Catherine, Gunda, Sreeharsha, Owenson, Venetia, Hoffmann, Scott, Sutton, Daniel, Jones, Stewart, Goodwin, Richard J. A., Willis, Brandon S., Rooney, Claire, de Bruin, Elza C., et al |
| Source: | NPJ breast cancer 9/19/2023; Vol. 9 (1). |
| Journal Info: | Publisher: Springer Nature ISSN: 2374-4677 |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-023-00575-6 |
